TET2 Inhibits VHL-Deficient ccRCC by Targeting HIF Signaling
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
TET2 suppresses VHL deficiency-driven clear cell renal cell carcinoma by inhibiting HIF signaling
Cancer Res 2022 Feb 17;[EPub Ahead of Print], X Zhang, S Li, J He, YJ Jin, R Zhang, W Dong, M Lin, Y Yang, T Tian, Y Zhou, Y Xu, QY Lei, J Zhang, Q Zhang, Y Xu, L LvFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.